The study included fifty patients with chronic-phase CML, who were categorized into two groups: responders (n = 26) and non-responders (n = 24), according to their BCR-ABL1 transcription levels after 12 months of imatinib treatment. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.